Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 721-736

  Perez Pinero C ^a   Bruzzone, A ^a   Sarappa, M G ^a   Castillo, L F ^a   Luthy I A ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

adrenoceptors; isoprenaline; mammary tumour; propranolol; rauwolscine; salbutamol

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROPRANOLOL; RAUWOLSCINE; SALBUTAMOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ALBUTEROL; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; ISOPROTERENOL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROPRANOLOL; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-2; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOHIMBINE;

EID: 84859922249     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01791.x     Document Type: Article

References (77)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Beliveau R, (2009). Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60: 438-445.
3. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, et al,. (2006). The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6: 240-248. (Pubitemid 43292567)
4. Antoni MH, Lechner S, Diaz A, Vargas S, Holley H, Phillips K, et al,. (2009). Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun 23: 580-591.
5. Badino GR, Novelli A, Girardi C, Di Carlo F, (1996). Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 33: 255-260. (Pubitemid 26383686)
6. Baker JG, Hall IP, Hill SJ, (2003). Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64: 1357-1369. (Pubitemid 37532226)
7. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K, (2011). Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29: 2635-2644.
8. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS, (1986). Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83: 2496-2500. (Pubitemid 16026909)
9. Bruzzone A, Pinero CP, Castillo LF, Sarappa MG, Rojas P, Lanari C, et al,. (2008). Alpha(2)-Adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol 155: 494-504.
10. Bruzzone A, Vanzulli SI, Soldati R, Giulianelli S, Lanari C, Luthy IA, (2009). Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J Cell Physiol 219: 477-484.
11. Bruzzone A, Pinero CP, Rojas P, Romanato M, Gass H, Lanari C, et al,. (2011). Alpha(2)-adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Curr Cancer Drug Targets 11: 763-774.
12. Cakir Y, Plummer HK, III, Tithof PK, Schuller HM, (2002). Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 21: 153-157.
13. Carie AE, Sebti SM, (2007). A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26: 3777-3788. (Pubitemid 46878138)
14. Cazzola M, Matera MG, (2008). Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155: 291-299.
15. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S, (2009). Catecholamines regulate tumor angiogenesis. Cancer Res 69: 3727-3730.
16. Clegg RA, Mullaney I, (1985). Acute change in the cyclic AMP content of rat mammary acini in vitro. Influence of physiological and pharmacological agents. Biochem J 230: 239-246. (Pubitemid 16247290)
17. Desai AN, Standifer KM, Eikenburg DC, (2004). Simultaneous alpha2B- and beta2-adrenoceptor activation sensitizes the alpha2B-adrenoceptor for agonist-induced down-regulation. J Pharmacol Exp Ther 311: 794-802. (Pubitemid 39391569)
18. Desai AN, Standifer KM, Eikenburg DC, (2005). Cellular G protein-coupled receptor kinase levels regulate sensitivity of the {alpha}2b-adrenergic receptor to undergo agonist-induced down-regulation. J Pharmacol Exp Ther 312: 767-773. (Pubitemid 40189577)
19. Dowdy S, Wearden S, (1983). Statistics for Research. John Wiley & Sons, Inc: New York.
20. Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J, (1991). Beta-adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11: 677-680.
21. Feigelson HS, Teras LR, Diver WR, Tang W, Patel AV, Stevens VL, et al,. (2008). Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res 10: R57.
22. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
23. Figueroa XF, Poblete I, Fernandez R, Pedemonte C, Cortes V, Huidobro-Toro JP, (2009). NO production and eNOS phosphorylation induced by epinephrine through the activation of beta-adrenoceptors. Am J Physiol Heart Circ Physiol 297: H134-H143.
24. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW, (2011). Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129: 549-556.
25. Granier S, Kim S, Shafer AM, Ratnala VR, Fung JJ, Zare RN, et al,. (2007). Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem 282: 13895-13905. (Pubitemid 47100565)
26. Hammon HM, Bruckmaier RM, Honegger UE, Blum JW, (1994). Distribution and density of alpha- and beta-adrenergic receptor binding sites in the bovine mammary gland. J Dairy Res 61: 47-57.
27. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, et al,. (2007). Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci 81: 399-404. (Pubitemid 47077434)
28. Houslay MD, Baillie GS, (2003). The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. Biochem Soc Trans 31: 1186-1190. (Pubitemid 38030936)
29. Inderwies T, Pfaffl MW, Meyer HH, Blum JW, Bruckmaier RM, (2003). Detection and quantification of mRNA expression of alpha- and beta-adrenergic receptor subtypes in the mammary gland of dairy cows. Domest Anim Endocrinol 24: 123-135. (Pubitemid 36238324)
30. Insel PA, (2011). Beta(2)-Adrenergic receptor polymorphisms and signaling: do variants influence the 'memory' of receptor activation? Sci Signal 4: pe37.
31. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC.
32. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council (2011). Guide for the Care and Use of Laboratory Animals, Eighth edn. National Academy Press: Washington, DC.
33. Jadhav VM, Tolat SN, (2010). Dramatic response of propranolol in hemangioma: report of two cases. Indian J Dermatol Venereol Leprol 76: 691-694.
34. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90.
35. Johnson M, (2006). Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117: 18-24. (Pubitemid 43017132)
36. Katritch V, Reynolds KA, Cherezov V, Hanson MA, Roth CB, Yeager M, et al,. (2009). Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J Mol Recognit 22: 307-318.
37. Kim EK, Choi EJ, (2010). Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
38. Lamb CA, Helguero LA, Giulianelli S, Soldati R, Vanzulli SI, Molinolo A, et al,. (2005). Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. Breast Cancer Res 7: R1111-R1121.
39. Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, et al,. (2001). Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61: 293-302. (Pubitemid 32095730)
40. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, et al,. (2009). The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16: 333-350.
41. Landen CN, Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, et al,. (2007). Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 67: 10389-10396. (Pubitemid 350070814)
42. Lavandero S, Donoso E, Sapag-Hagar M, (1985). Beta-adrenergic receptors in rat mammary gland. Biochem Pharmacol 34: 2034-2036. (Pubitemid 15026099)
43. Luthy IA, Bruzzone A, Pinero CP, Castillo LF, Chiesa IJ, Vazquez SM, et al,. (2009). Adrenoceptors: non-conventional target for breast cancer? Curr Med Chem 16: 1850-1862.
44. Marchetti B, Labrie F, (1990). Hormonal regulation of beta-adrenergic receptors in the rat mammary gland during the estrous cycle and lactation: role of sex steroids and prolactin. Endocrinology 126: 575-581. (Pubitemid 20037191)
45. Marchetti B, Spinola PG, Plante M, Poyet P, Follea N, Pelletier G, et al,. (1989). Beta-adrenergic receptors in DMBA-induced rat mammary tumors: correlation with progesterone receptor and tumor growth. Breast Cancer Res Treat 13: 251-263. (Pubitemid 19193195)
46. Marchetti B, Fortier MA, Poyet P, Follea N, Pelletier G, Labrie F, (1990). Beta-adrenergic receptors in the rat mammary gland during pregnancy and lactation: characterization, distribution, and coupling to adenylate cyclase. Endocrinology 126: 565-574. (Pubitemid 20037190)
47. Marchetti B, Spinola PG, Pelletier G, Labrie F, (1991). A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol 38: 307-320.
48. Masur K, Niggemann B, Zanker KS, Entschladen F, (2001). Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61: 2866-2869. (Pubitemid 32691927)
49. Mebratu Y, Tesfaigzi Y, (2009). How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-1175.
50. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al,. (2011). Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29: 2645-2652.
51. Nevzorova J, Evans BA, Bengtsson T, Summers RJ, (2006). Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. Br J Pharmacol 147: 446-454. (Pubitemid 43292287)
52. Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, et al,. (2005). A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 65: 732-742. (Pubitemid 40220345)
53. Palm D, Lang K, Niggemann B, TLt D, Masur K, Zaenker KS, et al,. (2006). The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118: 2744-2749. (Pubitemid 43673352)
54. Parkin DM, (2009). Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45: 1649-1653.
55. Philipp M, Hein L, (2004). Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol Ther 101: 65-74. (Pubitemid 38068526)
56. Plummer HK, III, Yu Q, Cakir Y, Schuller HM, (2004). Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer 4: 93.
57. Powe DG, Entschladen F, (2011). Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nat Rev. Clin Oncol 8: 511-512.
58. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, et al,. (2010). Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1: 628-638.
59. Roets E, Peeters G, Leysen JE, (1984). Identification of beta-adrenoceptors in bovine teat muscles by 3H-dihydroalprenolol binding. Arch Int Pharmacodyn Ther 270: 203-214. (Pubitemid 14089251)
60. Roets E, Vandeputte-Van Messom G, Peeters G, (1986). Relationship between milkability and adrenoceptor concentrations in teat tissue in primiparous cows. J Dairy Sci 69: 3120-3130.
61. Schwencke C, Schmeisser A, Weinbrenner C, Braun-Dullaeus RC, Marquetant R, Strasser RH, (2005). Transregulation of the alpha2-adrenergic signal transduction pathway by chronic beta-blockade: a novel mechanism for decreased platelet aggregation in patients. J Cardiovasc Pharmacol 45: 253-259. (Pubitemid 40328148)
62. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ, (2000). Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60: 153-166. (Pubitemid 30307475)
63. Soltoff SP, Hedden L, (2010). Isoproterenol and cAMP block ERK phosphory0lation and enhance [Ca2+]i increases and oxygen consumption by muscarinic receptor stimulation in rat parotid and submandibular acinar cells. J Biol Chem 285: 13337-13348.
64. Tan ST, Itinteang T, Leadbitter P, (2011). Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 64: 292-299.
65. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al,. (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12: 939-944. (Pubitemid 44175146)
66. United Kingdom Co-ordinating Committee on Cancer Research U (1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10.
67. Vandewalle B, Revillion F, Lefebvre J, (1990). Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116: 303-306.
68. Vazquez SM, Pignataro O, Luthy IA, (1999). Alpha2-adrenergic effect on human breast cancer MCF-7 cells. Breast Cancer Res Treat 55: 41-49. (Pubitemid 29353973)
69. Vazquez SM, Mladovan A, Garbovesky C, Baldi A, Luthy IA, (2004). Three novel hormone-responsive cell lines derived from primary human breast carcinomas: functional characterization. J Cell Physiol 199: 460-469. (Pubitemid 38580442)
70. Vazquez SM, Mladovan AG, Perez C, Bruzzone A, Baldi A, Luthy IA, (2006). Human breast cell lines exhibit functional alpha(2)-adrenoceptors. Cancer Chemother Pharmacol 58: 50-61.
71. Violin JD, DiPilato LM, Yildirim N, Elston TC, Zhang J, Lefkowitz RJ, (2008). beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics. J Biol Chem 283: 2949-2961.
72. Wang JF, Min JY, Hampton TG, Amende I, Yan X, Malek S, et al,. (2008). Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol 592: 123-127.
73. Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH, (2007). Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 97: 279-287. (Pubitemid 47073845)
74. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al,. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
75. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, et al,. (2006). Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2: 417-422. (Pubitemid 44114919)
76. Yuan A, Li Z, Li X, Yi S, Wang S, Cai Y, et al,. (2010). The mitogenic effectors of isoproterenol in human hepatocellular carcinoma cells. Oncol Rep 23: 151-157.
77. Zhu T, Gobeil F, Vazquez-Tello A, Leduc M, Rihakova L, Bossolasco M, et al,. (2006). Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can J Physiol Pharmacol 84: 377-391. (Pubitemid 44481100)